Evidence map›Paper›PMID 37239214›Full record

ArticleBrain sciences2023

Application of Pseudo-Three-Dimensional Residual Network to Classify the Stages of Moyamoya Disease.

Jiawei Xu, Jie Wu, Yu Lei, Yuxiang Gu

Abstract read
In one paragraph

Article in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiawei XuSchool of Health Science & Engineering, University of Shanghai for Science & Technology, Shanghai 200093, China.
Jie WuSchool of Health Science & Engineering, University of Shanghai for Science & Technology, Shanghai 200093, China.
Yu LeiDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yuxiang GuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is essential to assess the condition of moyamoya disease (MMD) patients accurately and promptly to prevent MMD from endangering their lives. A Pseudo-Three-Dimensional Residual Network (P3D ResNet) was proposed to process spatial and temporal information, which was implemented in the identification of MMD stages. Digital Subtraction Angiography (DSA) sequences were split into mild, moderate and severe stages in accordance with the progression of MMD, and divided into a training set, a verification set, and a test set with a ratio of 6:2:2 after data enhancement. The features of the DSA images were processed using decoupled three-dimensional (3D) convolution. To increase the receptive field and preserve the features of the vessels, decoupled 3D dilated convolutions that are equivalent to two-dimensional dilated convolutions, plus one-dimensional dilated convolution, were utilized in the spatial and temporal domains, respectively. Then, they were coupled in serial, parallel, and serial-parallel modes to form P3D modules based on the structure of the residual unit. The three kinds of module were placed in a proper sequence to create the complete P3D ResNet. The experimental results demonstrate that the accuracy of P3D ResNet can reach 95.78% with appropriate parameter quantities, making it easy to implement in a clinical setting.

Indexed as

deep learningDigital Subtraction Angiographydilated convolutionfeature extractionmoyamoya diseasePseudo-Three-Dimensional Residual Network

Identifiers

PMID37239214
PMCPMC10216656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.